Gene Therapies
Therapy
Health

Spark Therapeutics

$107.64
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.82 (-0.76%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ONCE and other stocks, options, ETFs, and crypto commission-free!

About

Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. Read More The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA.

Employees
368
Headquarters
Philadelphia, Pennsylvania
Founded
2013
Market Cap
4.13B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
950.02K
High Today
$108.98
Low Today
$107.64
Open Price
$108.47
Volume
127.19K
52 Week High
$114.20
52 Week Low
$34.53

Collections

Gene Therapies
Therapy
Health
Research And Development
Biotechnology
Technology

News

Wall Street JournalMay 7

A $2 Million Drug Is About to Hit the Market

352
Yahoo FinanceMay 7

Will Spark Therapeutics (ONCE) Report Negative Q1 Earnings? What You Should Know

Wall Street expects a year-over-year increase in earnings on higher revenues when Spark Therapeutics (ONCE) reports results for the quarter ended March 2019. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.

91
StreetInsiderApr 26

Form SC TO-T/A Spark Therapeutics, Inc. Filed by: ROCHE HOLDINGS INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 5) SPARK THERAPEUTICS, INC. (Name of Subject Company) 022019 MERGER SUBSIDIARY, INC. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing Persons—Offeror) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 84652J103 (Cusip Number of ...

23

Earnings

-$1.90
-$1.30
-$0.70
-$0.10
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$1.18 per share
Actual
Expected May 23, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.